Diaceutics PLC (AIM:DXRX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
174.17
-0.33 (-0.19%)
Apr 28, 2026, 3:46 PM GMT
46.98%
Market Cap 146.03M
Revenue (ttm) 34.40M
Net Income (ttm) -1.52M
Shares Out 84.65M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE 278.23
Dividend n/a
Ex-Dividend Date n/a
Volume 14,631
Average Volume 210,114
Open 172.00
Previous Close 174.50
Day's Range 170.00 - 174.17
52-Week Range 112.25 - 177.00
Beta 0.94
RSI 77.54
Earnings Date May 27, 2026

About Diaceutics

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 2005
Employees 213
Stock Exchange London Stock Exchange AIM
Ticker Symbol DXRX
Full Company Profile

Financial Performance

In 2024, Diaceutics's revenue was 32.16 million, an increase of 35.69% compared to the previous year's 23.70 million. Losses were -1.70 million, -2.46% less than in 2023.

Financial Statements

News

Diaceutics Earnings Call Transcript: H2 2024

2024 marked a breakout year with 39% revenue growth, strong recurring revenue, and major U.S. expansion. The business is shifting to profitability in 2025, driven by new enterprise contracts, PMx solution launches, and robust order book visibility. Growth is underpinned by high margins, a leading pharma client base, and continued investment in AI and data.

1 year ago - Transcripts

Diaceutics Earnings Call Transcript: H1 2024

Delivered strong H1 2024 growth with revenue up 24% and gross margin at 87%, driven by the launch of PMX and expansion in rare disease and Europe. PMX is expected to significantly boost revenue per brand, and the business is on track for profitability and cash flow in 2025.

1 year ago - Transcripts

Diaceutics Transcript: CME 2024

Transitioning to a high-margin, recurring revenue model, the business leverages a proprietary global lab network and AI-driven DXRX platform to deliver daily insights for pharma clients. Strategic partnerships, expanded operations, and a robust roadmap position it for growth in oncology and non-oncology markets.

2 years ago - Transcripts

Diaceutics Transcript: CMD 2021

5 years ago - Transcripts